120:(F-18) to see how it metabolized in the tissues of different organs. This group studied how long it took the lungs, liver, kidneys, heart, and brain to metabolize radioactive glucose. They found the molecule distributed uniformly, and then, after two hours, only the heart and the brain had significant levels of radioactivity from the F-18 due to metabolic trapping. This trapping occurred because once the glucose was pulled into the cells, the glucose was
22:
233:(Miele, E.; Spinelli, G. P.; Tomao, F.; Zullo, A.; De Marinis, F.; Pasciuti, G.; Rossi, L.; Zoratto, F.; Tomao, S. Positron Emission Tomography (PET) radiotracers in oncology–utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). Journal of Experimental & Clinical Cancer Research 2008, 27, 52.)
137:
derivatives, which were synthesized using F-18, to label prostate cancer. The experiments were conducted first in mice and then in human patients. Choline (CH) and choline radiolabeled with F-18 (FCH) were both found to primarily migrate to the kidneys and liver in their experiment. This is different
124:
to cause the concentration of glucose in the cell to appear lower than it is, which then promotes the transport of more glucose. This phosphorylation of the radioactive glucose caused the metabolic trapping in the heart and the brain. The lungs, liver, and kidneys did not experience metabolic
261:
DeGrado, T. R.; Coleman, R. E.; Wang, S.; Baldwin, S. W.; Orr, M. D.; Robertson, C. N.; Polascik, T. J.; Price, D. T. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001, 61,
129:
requires the hydroxyl (-OH) group found on the C-2 position of the sugar, where the F-18 atom was placed. Without the active transport, the radiolabeled glucose that was not trapped was then excreted as waste instead of being phosphorylated in the cell.
125:
trapping, and the radioactive glucose that was not trapped was excreted in the urine. F-18 radiolabeled glucose did not get collected by the kidneys and cycled back into the system, as it would do for normal glucose. This suggests that the
138:
from the earlier experiment with glucose due to the difference in mechanism and metabolic need of glucose versus choline in the body. Phosphorylation was again found to be responsible for the trapping of the tracer in the tissues.
115:
In order to use it as a diagnostic tool in medicine, scientists have studied the trapping of radioactive molecules within different tissues throughout the body. In 1978, Gallagher et al. studied glucose tagged with
40:
244:
Metabolic
Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for the Biodistribution of 2-Deoxy-2-Fluoro-D-Glucose
216:
Metabolic
Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for the Biodistribution of 2-Deoxy-2-Fluoro-D-Glucose
112:) scan, an effective tool for detecting tumors, as there is a greater uptake of the target molecule by tumor tissue than by normal tissue.
205:
probe in biochemistry is: Any group of atoms or molecules radioactively labeled in order to study a given molecule or other structure
278:
58:
246:
218:
74:
refers to a localization mechanism of synthesized radiocompounds in the human body. It can be defined as the
109:
36:
168:
147:
91:
8:
283:
167:
Fowler, J.; Logan, J.; Volkow, N. D.; Wang, G. J.; MacGregor, R. R.; Ding, Y. S. (2002).
83:
79:
184:
243:
215:
188:
180:
126:
87:
121:
272:
75:
192:
117:
98:
95:
134:
169:"Monoamine oxidase: Radiotracer development and human studies"
102:
166:
108:
Metabolic trapping is the mechanism underlying the (
31:
may be too technical for most readers to understand
270:
90:. It is a basic principle of the design of
59:Learn how and when to remove this message
43:, without removing the technical details.
133:A 2001 study of metabolic trapping used
271:
41:make it understandable to non-experts
15:
13:
14:
295:
242:. Gallagher, Brian M and et al.
214:. Gallagher, Brian M and et al.
20:
247:The Journal of Nuclear Medicine
219:The Journal of Nuclear Medicine
255:
236:
227:
208:
199:
160:
1:
185:10.1016/S1046-2023(02)00083-X
153:
7:
141:
10:
300:
101:for functional studies or
279:Medicinal radiochemistry
82:based on the relative
148:Metabolic imprinting
92:radiopharmaceuticals
127:active transporter
84:metabolic activity
80:radioactive tracer
78:accumulation of a
72:Metabolic trapping
69:
68:
61:
291:
263:
259:
253:
240:
234:
231:
225:
212:
206:
203:
197:
196:
164:
64:
57:
53:
50:
44:
24:
23:
16:
299:
298:
294:
293:
292:
290:
289:
288:
269:
268:
267:
266:
260:
256:
241:
237:
232:
228:
213:
209:
204:
200:
165:
161:
156:
144:
65:
54:
48:
45:
37:help improve it
34:
25:
21:
12:
11:
5:
297:
287:
286:
281:
265:
264:
254:
235:
226:
207:
198:
179:(3): 263–277.
158:
157:
155:
152:
151:
150:
143:
140:
122:phosphorylated
86:of the body's
67:
66:
49:September 2015
28:
26:
19:
9:
6:
4:
3:
2:
296:
285:
282:
280:
277:
276:
274:
258:
252:
249:19:1154-1161,
248:
245:
239:
230:
224:
221:19:1154-1161,
220:
217:
211:
202:
194:
190:
186:
182:
178:
174:
170:
163:
159:
149:
146:
145:
139:
136:
131:
128:
123:
119:
113:
111:
106:
104:
100:
97:
93:
89:
85:
81:
77:
76:intracellular
73:
63:
60:
52:
42:
38:
32:
29:This article
27:
18:
17:
257:
250:
238:
229:
222:
210:
201:
176:
172:
162:
132:
114:
107:
71:
70:
55:
46:
30:
118:Fluorine-18
284:Metabolism
273:Categories
154:References
105:location.
96:metabolic
262:110-117.
193:12183115
142:See also
173:Methods
135:choline
88:tissues
35:Please
191:
99:probes
103:tumor
251:1978
223:1978
189:PMID
181:doi
110:PET
94:as
39:to
275::
187:.
177:27
175:.
171:.
195:.
183::
62:)
56:(
51:)
47:(
33:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.